News | March 30, 2026
Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
As Tracky launches integrated health solution
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Subscribe To Our Newsletter & Stay Updated
